Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was...
Gespeichert in:
| Veröffentlicht in: | Nature medicine 1998-03, Vol.4 (3), p.321-327 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 327 |
|---|---|
| container_issue | 3 |
| container_start_page | 321 |
| container_title | Nature medicine |
| container_volume | 4 |
| creator | Rosenberg, Steven A. Yang, James C. Schwartzentruber, Douglas J. Hwu, Patrick Marincola, Francesco M. Topalian, Suzanne L. Restifo, Nicholas P. Dudley, Mark E. Schwarz, Susan L. Spiess, Paul J. Parkhurst, Maria R. Kawakami, Yutaka Seipp, Claudia A. Einhorn, Jan H. White, Donald E. |
| description | The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies. |
| doi_str_mv | 10.1038/nm0398-321 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2064864</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79723471</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-9414f6994d82715d3d0540b561ddaa3283666ebde865a0fd244e74874347733d3</originalsourceid><addsrcrecordid>eNqFUUtrFTEUHkSptbpxLwQEF5XRZJLJY1OQUrVQcKPgLuROztybMknGJHOl4I83w73UB4KrnPA9zuNrmucEvyGYyrfBY6pkSzvyoDklPeMtEfjrw1pjIVupev64eZLzLcaY4l6dNCeqx5hjftr8uPZ-CXGKWzcgEywqO0hmhqXUP-zNtJjiYkBxRAblu1DhFZlhLs4C2pthcAHQGNOqRCWBKR5CWQVzldYyo--u7JCHYnIxq9rDZEL05mnzaDRThmfH96z58v7q8-XH9ubTh-vLdzftwLgsrWKEjVwpZmUnSG-pxT3Dm54Ta42hnaScc9hYkLw3eLQdYyCYFIwyISi19Ky5OPjOy8aDHepQyUx6Ts6bdKejcfpPJLid3sa97jBnkrNq8OpokOK3BXLR3uUBproGxCVroURXm5H_EglfZ-KiEl_-RbyNSwr1CrrjqqccE6kq6_zAGlLMOcF4PzPBeo1eH6LXNfpKfvH7lvfUY9YVf33Ac0XCFtKvlv9w-wkh97mz</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2695360189</pqid></control><display><type>article</type><title>Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Nature Journals Online</source><creator>Rosenberg, Steven A. ; Yang, James C. ; Schwartzentruber, Douglas J. ; Hwu, Patrick ; Marincola, Francesco M. ; Topalian, Suzanne L. ; Restifo, Nicholas P. ; Dudley, Mark E. ; Schwarz, Susan L. ; Spiess, Paul J. ; Parkhurst, Maria R. ; Kawakami, Yutaka ; Seipp, Claudia A. ; Einhorn, Jan H. ; White, Donald E.</creator><creatorcontrib>Rosenberg, Steven A. ; Yang, James C. ; Schwartzentruber, Douglas J. ; Hwu, Patrick ; Marincola, Francesco M. ; Topalian, Suzanne L. ; Restifo, Nicholas P. ; Dudley, Mark E. ; Schwarz, Susan L. ; Spiess, Paul J. ; Parkhurst, Maria R. ; Kawakami, Yutaka ; Seipp, Claudia A. ; Einhorn, Jan H. ; White, Donald E.</creatorcontrib><description>The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies.</description><identifier>ISSN: 1078-8956</identifier><identifier>EISSN: 1546-170X</identifier><identifier>DOI: 10.1038/nm0398-321</identifier><identifier>PMID: 9500606</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>Adult ; Antigens ; Biomedical and Life Sciences ; Biomedicine ; Cancer ; Cancer immunotherapy ; Cancer Research ; Cancer vaccines ; Cancer Vaccines - therapeutic use ; Cloning ; Drug Therapy, Combination ; Evaluation Studies as Topic ; Female ; Genes ; Glycoprotein gp100 ; gp100 Melanoma Antigen ; Histocompatibility antigen HLA ; HLA-A2 Antigen - immunology ; Humans ; Immunization ; Infectious Diseases ; Interleukin 2 ; Interleukin-2 - therapeutic use ; Lung Neoplasms - secondary ; Lung Neoplasms - therapy ; Melanoma ; Melanoma - therapy ; Melanoma-associated antigen ; Membrane Glycoproteins - therapeutic use ; Metabolic Diseases ; Metastases ; Middle Aged ; Molecular Medicine ; Neoplasm Metastasis ; Neurosciences ; Oligopeptides - therapeutic use ; Patients ; Peptide Fragments - therapeutic use ; Peptides ; Vaccines</subject><ispartof>Nature medicine, 1998-03, Vol.4 (3), p.321-327</ispartof><rights>Springer Nature America, Inc. 1998</rights><rights>Nature Publishing Group 1998.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-9414f6994d82715d3d0540b561ddaa3283666ebde865a0fd244e74874347733d3</citedby><cites>FETCH-LOGICAL-c468t-9414f6994d82715d3d0540b561ddaa3283666ebde865a0fd244e74874347733d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/nm0398-321$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/nm0398-321$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9500606$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rosenberg, Steven A.</creatorcontrib><creatorcontrib>Yang, James C.</creatorcontrib><creatorcontrib>Schwartzentruber, Douglas J.</creatorcontrib><creatorcontrib>Hwu, Patrick</creatorcontrib><creatorcontrib>Marincola, Francesco M.</creatorcontrib><creatorcontrib>Topalian, Suzanne L.</creatorcontrib><creatorcontrib>Restifo, Nicholas P.</creatorcontrib><creatorcontrib>Dudley, Mark E.</creatorcontrib><creatorcontrib>Schwarz, Susan L.</creatorcontrib><creatorcontrib>Spiess, Paul J.</creatorcontrib><creatorcontrib>Parkhurst, Maria R.</creatorcontrib><creatorcontrib>Kawakami, Yutaka</creatorcontrib><creatorcontrib>Seipp, Claudia A.</creatorcontrib><creatorcontrib>Einhorn, Jan H.</creatorcontrib><creatorcontrib>White, Donald E.</creatorcontrib><title>Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma</title><title>Nature medicine</title><addtitle>Nat Med</addtitle><addtitle>Nat Med</addtitle><description>The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies.</description><subject>Adult</subject><subject>Antigens</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer</subject><subject>Cancer immunotherapy</subject><subject>Cancer Research</subject><subject>Cancer vaccines</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>Cloning</subject><subject>Drug Therapy, Combination</subject><subject>Evaluation Studies as Topic</subject><subject>Female</subject><subject>Genes</subject><subject>Glycoprotein gp100</subject><subject>gp100 Melanoma Antigen</subject><subject>Histocompatibility antigen HLA</subject><subject>HLA-A2 Antigen - immunology</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infectious Diseases</subject><subject>Interleukin 2</subject><subject>Interleukin-2 - therapeutic use</subject><subject>Lung Neoplasms - secondary</subject><subject>Lung Neoplasms - therapy</subject><subject>Melanoma</subject><subject>Melanoma - therapy</subject><subject>Melanoma-associated antigen</subject><subject>Membrane Glycoproteins - therapeutic use</subject><subject>Metabolic Diseases</subject><subject>Metastases</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Neoplasm Metastasis</subject><subject>Neurosciences</subject><subject>Oligopeptides - therapeutic use</subject><subject>Patients</subject><subject>Peptide Fragments - therapeutic use</subject><subject>Peptides</subject><subject>Vaccines</subject><issn>1078-8956</issn><issn>1546-170X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUUtrFTEUHkSptbpxLwQEF5XRZJLJY1OQUrVQcKPgLuROztybMknGJHOl4I83w73UB4KrnPA9zuNrmucEvyGYyrfBY6pkSzvyoDklPeMtEfjrw1pjIVupev64eZLzLcaY4l6dNCeqx5hjftr8uPZ-CXGKWzcgEywqO0hmhqXUP-zNtJjiYkBxRAblu1DhFZlhLs4C2pthcAHQGNOqRCWBKR5CWQVzldYyo--u7JCHYnIxq9rDZEL05mnzaDRThmfH96z58v7q8-XH9ubTh-vLdzftwLgsrWKEjVwpZmUnSG-pxT3Dm54Ta42hnaScc9hYkLw3eLQdYyCYFIwyISi19Ky5OPjOy8aDHepQyUx6Ts6bdKejcfpPJLid3sa97jBnkrNq8OpokOK3BXLR3uUBproGxCVroURXm5H_EglfZ-KiEl_-RbyNSwr1CrrjqqccE6kq6_zAGlLMOcF4PzPBeo1eH6LXNfpKfvH7lvfUY9YVf33Ac0XCFtKvlv9w-wkh97mz</recordid><startdate>19980301</startdate><enddate>19980301</enddate><creator>Rosenberg, Steven A.</creator><creator>Yang, James C.</creator><creator>Schwartzentruber, Douglas J.</creator><creator>Hwu, Patrick</creator><creator>Marincola, Francesco M.</creator><creator>Topalian, Suzanne L.</creator><creator>Restifo, Nicholas P.</creator><creator>Dudley, Mark E.</creator><creator>Schwarz, Susan L.</creator><creator>Spiess, Paul J.</creator><creator>Parkhurst, Maria R.</creator><creator>Kawakami, Yutaka</creator><creator>Seipp, Claudia A.</creator><creator>Einhorn, Jan H.</creator><creator>White, Donald E.</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7QO</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19980301</creationdate><title>Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma</title><author>Rosenberg, Steven A. ; Yang, James C. ; Schwartzentruber, Douglas J. ; Hwu, Patrick ; Marincola, Francesco M. ; Topalian, Suzanne L. ; Restifo, Nicholas P. ; Dudley, Mark E. ; Schwarz, Susan L. ; Spiess, Paul J. ; Parkhurst, Maria R. ; Kawakami, Yutaka ; Seipp, Claudia A. ; Einhorn, Jan H. ; White, Donald E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-9414f6994d82715d3d0540b561ddaa3283666ebde865a0fd244e74874347733d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Antigens</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer</topic><topic>Cancer immunotherapy</topic><topic>Cancer Research</topic><topic>Cancer vaccines</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>Cloning</topic><topic>Drug Therapy, Combination</topic><topic>Evaluation Studies as Topic</topic><topic>Female</topic><topic>Genes</topic><topic>Glycoprotein gp100</topic><topic>gp100 Melanoma Antigen</topic><topic>Histocompatibility antigen HLA</topic><topic>HLA-A2 Antigen - immunology</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infectious Diseases</topic><topic>Interleukin 2</topic><topic>Interleukin-2 - therapeutic use</topic><topic>Lung Neoplasms - secondary</topic><topic>Lung Neoplasms - therapy</topic><topic>Melanoma</topic><topic>Melanoma - therapy</topic><topic>Melanoma-associated antigen</topic><topic>Membrane Glycoproteins - therapeutic use</topic><topic>Metabolic Diseases</topic><topic>Metastases</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Neoplasm Metastasis</topic><topic>Neurosciences</topic><topic>Oligopeptides - therapeutic use</topic><topic>Patients</topic><topic>Peptide Fragments - therapeutic use</topic><topic>Peptides</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rosenberg, Steven A.</creatorcontrib><creatorcontrib>Yang, James C.</creatorcontrib><creatorcontrib>Schwartzentruber, Douglas J.</creatorcontrib><creatorcontrib>Hwu, Patrick</creatorcontrib><creatorcontrib>Marincola, Francesco M.</creatorcontrib><creatorcontrib>Topalian, Suzanne L.</creatorcontrib><creatorcontrib>Restifo, Nicholas P.</creatorcontrib><creatorcontrib>Dudley, Mark E.</creatorcontrib><creatorcontrib>Schwarz, Susan L.</creatorcontrib><creatorcontrib>Spiess, Paul J.</creatorcontrib><creatorcontrib>Parkhurst, Maria R.</creatorcontrib><creatorcontrib>Kawakami, Yutaka</creatorcontrib><creatorcontrib>Seipp, Claudia A.</creatorcontrib><creatorcontrib>Einhorn, Jan H.</creatorcontrib><creatorcontrib>White, Donald E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>Biotechnology Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nature medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rosenberg, Steven A.</au><au>Yang, James C.</au><au>Schwartzentruber, Douglas J.</au><au>Hwu, Patrick</au><au>Marincola, Francesco M.</au><au>Topalian, Suzanne L.</au><au>Restifo, Nicholas P.</au><au>Dudley, Mark E.</au><au>Schwarz, Susan L.</au><au>Spiess, Paul J.</au><au>Parkhurst, Maria R.</au><au>Kawakami, Yutaka</au><au>Seipp, Claudia A.</au><au>Einhorn, Jan H.</au><au>White, Donald E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma</atitle><jtitle>Nature medicine</jtitle><stitle>Nat Med</stitle><addtitle>Nat Med</addtitle><date>1998-03-01</date><risdate>1998</risdate><volume>4</volume><issue>3</issue><spage>321</spage><epage>327</epage><pages>321-327</pages><issn>1078-8956</issn><eissn>1546-170X</eissn><abstract>The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>9500606</pmid><doi>10.1038/nm0398-321</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-8956 |
| ispartof | Nature medicine, 1998-03, Vol.4 (3), p.321-327 |
| issn | 1078-8956 1546-170X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2064864 |
| source | MEDLINE; SpringerLink Journals; Nature Journals Online |
| subjects | Adult Antigens Biomedical and Life Sciences Biomedicine Cancer Cancer immunotherapy Cancer Research Cancer vaccines Cancer Vaccines - therapeutic use Cloning Drug Therapy, Combination Evaluation Studies as Topic Female Genes Glycoprotein gp100 gp100 Melanoma Antigen Histocompatibility antigen HLA HLA-A2 Antigen - immunology Humans Immunization Infectious Diseases Interleukin 2 Interleukin-2 - therapeutic use Lung Neoplasms - secondary Lung Neoplasms - therapy Melanoma Melanoma - therapy Melanoma-associated antigen Membrane Glycoproteins - therapeutic use Metabolic Diseases Metastases Middle Aged Molecular Medicine Neoplasm Metastasis Neurosciences Oligopeptides - therapeutic use Patients Peptide Fragments - therapeutic use Peptides Vaccines |
| title | Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T04%3A06%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunologic%20and%20therapeutic%20evaluation%20of%20a%20synthetic%20peptide%20vaccine%20for%20the%20treatment%20of%20patients%20with%20metastatic%20melanoma&rft.jtitle=Nature%20medicine&rft.au=Rosenberg,%20Steven%20A.&rft.date=1998-03-01&rft.volume=4&rft.issue=3&rft.spage=321&rft.epage=327&rft.pages=321-327&rft.issn=1078-8956&rft.eissn=1546-170X&rft_id=info:doi/10.1038/nm0398-321&rft_dat=%3Cproquest_pubme%3E79723471%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2695360189&rft_id=info:pmid/9500606&rfr_iscdi=true |